Zno nanoparticles induce dyslipidemia and atherosclerotic lesions leading to changes in vascular contractility and cannabinoid receptors expression as well as increased blood pressure

Adriana Ceballos-Gutiérrez, Alejandrina Rodríguez-Hernández, María Del Rosario Álvarez-Valadez, Saraí Limón-Miranda, Felipa Andrade, Alejandro Figueroa-Gutiérrez, Irene Díaz-Reval, Alejandro Apolinar-Iribe, Luis Castro-Sánchez, Javier Alamilla, Enrique Sánchez-Pastor*, Adolfo Virgen-Ortiz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

ZnO nanoparticles (ZnONPs) have been shown to have therapeutic potential in some diseases such as diabetes and cancer. However, concentration-dependent adverse effects have also been reported. Studies which evaluate the effects of ZnONPs on the cardiovascular system are scarce. This study aimed to evaluate the cardiovascular effects of a low dose of ZnONPs administered chronically in healthy rats. Changes in dyslipidemia biomarkers, blood pressure, aortic wall structure, vascular contractility, and expression of cannabinoid receptors in the aorta wall were evaluated. Healthy rats were divided into two groups: control or treated (one, two, and three months). The treated rats received an oral dose of 10 mg/kg/day. The results showed that treatment with ZnONPs induced dyslipidemia from the first month, increasing atherosclerosis risk, which was confirmed by presence of atherosclerotic alterations revealed by aorta histological analysis. In in vitro assays, ZnONPs modified the aorta contractile activity in response to the activation of cannabinoid receptors (CB1 and CB2 ). The expression of CB1 and CB2 was modified as well. Moreover, ZnONPs elicited an increase in blood pressure. In conclusion, long-time oral administration of ZnONPs induce dyslipidemia and atherosclerosis eliciting alterations in aorta contractility, CB1 and CB2 receptors expression, and an increase in blood pressure in healthy rats.

Original languageEnglish
Article number2319
JournalNanomaterials
Volume11
Issue number9
DOIs
StatePublished - Sep 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

  • Atherosclerosis
  • Blood pressure
  • CB receptor
  • CB receptor
  • Cannabinoid receptor
  • Cardiovascular
  • Dyslipidemia
  • Vascular contractility
  • ZnO nanoparticles

Fingerprint

Dive into the research topics of 'Zno nanoparticles induce dyslipidemia and atherosclerotic lesions leading to changes in vascular contractility and cannabinoid receptors expression as well as increased blood pressure'. Together they form a unique fingerprint.

Cite this